AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 and a Promising Oral Antiviral for Treatment of COVID-19.
Antimicrobial agents and chemotherapy • Vol. 65, Issue 4 • 2021
Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus.
PloS one • Vol. 15, Issue 1 • 2020
Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis.
Antimicrobial agents and chemotherapy • Vol. 63, Issue 12 • 2019
